Control of IFN-I responses by the aminopeptidase IRAP in neonatal C57BL/6 alveolar macrophages during RSV infection

Carole Drajac1, Daphné Laubreton1, Quentin Marquant1

  • 1INRAE, UVSQ, VIM, Université Paris-Saclay, Jouy-en-Josas, France.

Mucosal Immunology
|April 13, 2021
PubMed

Insights

Neonatal alveolar macrophages poorly respond to Respiratory Syncytial Virus (RSV) due to Insulin-Responsive AminoPeptidase (IRAP). Removing IRAP enhances antiviral defenses in infants, suggesting a new therapeutic target for RSV infections.

Area of Science:

  • Immunology
  • Virology
  • Neonatal Medicine

Background:

  • Respiratory Syncytial Virus (RSV) is a leading cause of infant lower respiratory tract infections.
  • Severe RSV bronchiolitis in neonates is linked to impaired type I interferon (IFN-I) production by alveolar macrophages (AMs).

Purpose of the Study:

  • To investigate the role of Insulin-Responsive AminoPeptidase (IRAP) in neonatal AM response to RSV.
  • To determine if targeting IRAP can enhance antiviral immunity in neonates.

Main Methods:

  • In vitro infection of neonatal and adult C57BL/6 AMs with RSV.
  • Comparison of IFN-I pathway activation and gene expression in wild-type and IRAP knockout (IRAPKO) neonatal AMs.
  • In vivo infection of newborn IRAPKO and wild-type mice with RSV.

Main Results:

  • Neonatal AMs showed weak IFN-I pathway activation and failed to control RSV replication.
  • IRAP deletion in neonatal AMs significantly increased IFN-I production and IFN-stimulated gene expression.
  • IRAP depletion did not alter adult AM responses to RSV.
  • Newborn IRAPKO mice exhibited enhanced lung IFN-I levels and more efficient viral clearance compared to wild-type neonates.

Conclusions:

  • Early-life susceptibility to RSV may stem from IRAP's age-dependent suppressive effect on neonatal AM antiviral responses.
  • IRAP represents a potential therapeutic target to bolster infant immunity against RSV.